Facebook enhances antidepressant pharmacotherapy effects

Area of Science:

• Psychiatry
• Digital Therapeutics
• Mental Health Technology

Background:

• Treatment-resistant major depressive disorder (TR-MDD) presents significant challenges with low remission rates.
• Internet-based psychotherapies show promise for major depressive disorder (MDD), but research in TR-MDD is limited.
• The use of social media platforms like Facebook in conjunction with psychiatric care has not been previously studied in TR-MDD.

Purpose of the Study:

• To investigate the efficacy of Facebook as an adjunctive therapy for TR-MDD.
• To compare outcomes between TR-MDD patients using Facebook with a psychiatrist as a "friend" versus without.
• To evaluate Facebook's potential as an enhancement to standard pharmacotherapy.

Main Methods:

• Sixty TR-MDD patients were randomized into three groups: Facebook with psychiatrist "friend," Facebook without psychiatrist "friend," and a control group.
• Participants in Facebook groups engaged for at least 1 hour daily for 3 months.
• Depressive symptoms were assessed using HAD17 and BDI-II at baseline and monthly intervals.

Main Results:

• Both Facebook intervention groups demonstrated significant reductions in HAD17 and BDI-II scores compared to the control group.
• Higher remission and response rates were observed in the Facebook groups.
• The group where the psychiatrist was a "friend" on Facebook showed superior outcomes.

Conclusions:

• Facebook can serve as an effective enhancement therapy for TR-MDD when used adjunctively with pharmacotherapy.
• Psychiatrist involvement as an online "friend" on Facebook may yield better therapeutic results in TR-MDD.
• This study highlights the potential of social media platforms in augmenting mental health treatment.